Chemical Pathology, National Health Laboratory Service, Durban, Kwa-Zulu Natal, South Africa.
Chemical Pathology, University of KwaZulu-Natal, Durban, Kwa-Zulu-Natal, South Africa.
Clin Chem Lab Med. 2020 Oct 20;59(4):687-692. doi: 10.1515/cclm-2020-0827. Print 2021 Mar 26.
Rejections of clinical chemistry specimens delays the availability of results, which may impact patient management. The study aims to measure sample rejection rate, identify reasons for sample rejection, evaluate the effect of a campaign to reduce rejection rates and discover which clinical units produced the most insufficient specimen.
The study measured specimen rejection rates and the contributions of different rejection reasons in calendar 2016 and April 2018-March 2019. The study undertook a 7-intervention campaign to reduce specimen rejection during the 2018-2019 intervention period. It compared rejections rates, number of months with rejection rates ≤1.2%, and distribution of rejection reasons between the two year-long intervals. The study also determined the origin for specimens rejected for the most common rejection reason during one month in the second period.
The overall rejection rate fell significantly from 1.4% in pre-intervention period to 1.2% in the intervention period. The number of months with rejection rates within the target range increased significantly from 2 in the post-intervention period to 6 in the intervention period. Insufficient, hemolysed, and 'too-old' specimen decreased significantly, however, insufficient specimen remained the most frequent rejection reason. In February 2019, one-third of all insufficient specimen came from neonatal units and 24% from the pediatric units.
Interventions decreased significantly both overall and monthly rejection rates above target levels. Insufficient, hemolysed, 'too-old' specimen, became significantly less frequent, however, insufficient specimen remained the most frequent rejection reason. Over a month, most insufficient specimen came from neonatal and pediatric sites.
临床化学标本的拒收会延迟结果的可获得性,从而可能影响患者的管理。本研究旨在测量标本拒收率,确定拒收原因,评估降低拒收率的活动效果,并发现哪些临床科室产生的标本不足。
本研究在 2016 年日历年度和 2018 年 4 月至 2019 年 3 月期间测量了标本拒收率和不同拒收原因的贡献。在 2018-2019 年干预期间,本研究进行了一项 7 项干预措施的活动,以降低标本拒收率。它比较了两个为期一年的间隔内的拒收率、拒收率≤1.2%的月份数和拒收原因的分布。本研究还确定了在第二个期间的一个月内,由于最常见的拒收原因而拒收的标本的来源。
整体拒收率从干预前的 1.4%显著下降到干预期间的 1.2%。拒收率在目标范围内的月份数从干预后的 2 个显著增加到干预期间的 6 个。标本不足、溶血和“太老”的标本显著减少,但标本不足仍然是最常见的拒收原因。在 2019 年 2 月,三分之一的不足标本来自新生儿病房,24%来自儿科病房。
干预措施显著降低了总体和每月超过目标水平的拒收率。标本不足、溶血、“太老”的标本显著减少,但标本不足仍然是最常见的拒收原因。在一个月的时间里,大多数不足的标本来自新生儿和儿科病房。